Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Madan S, et al. Among authors: zeldenrust s. Blood. 2011 Aug 18;118(7):1763-5. doi: 10.1182/blood-2011-04-350009. Epub 2011 Jun 14. Blood. 2011. PMID: 21673347 Free PMC article.
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Dispenzieri A, et al. Among authors: zeldenrust s. Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822. Am J Hematol. 2010. PMID: 20872958 Free PMC article.
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668. Epub 2010 Aug 26. Blood. 2010. PMID: 20798235 Free PMC article.
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14. Blood. 2017. PMID: 28807981 Free article.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Lacy MQ, et al. Among authors: zeldenrust s. Blood. 2011 Sep 15;118(11):2970-5. doi: 10.1182/blood-2011-04-348896. Epub 2011 Jun 20. Blood. 2011. PMID: 21690557 Free PMC article. Clinical Trial.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. D'Souza A, et al. Among authors: zeldenrust s. Blood. 2011 Oct 27;118(17):4663-5. doi: 10.1182/blood-2011-06-362392. Epub 2011 Aug 31. Blood. 2011. PMID: 21881050 Free article.
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience.
D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. D'Souza A, et al. Among authors: zeldenrust s. Blood. 2012 Jul 5;120(1):56-62. doi: 10.1182/blood-2012-04-423178. Epub 2012 May 18. Blood. 2012. PMID: 22611150 Free article.
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Blood. 2017 Jan 5;129(1):82-87. doi: 10.1182/blood-2016-06-721878. Epub 2016 Oct 11. Blood. 2017. PMID: 27729322 Free article.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Muchtar E, et al. Among authors: zeldenrust s. Blood. 2017 Apr 13;129(15):2111-2119. doi: 10.1182/blood-2016-11-751628. Epub 2017 Jan 26. Blood. 2017. PMID: 28126928 Free PMC article. Clinical Trial.
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Nandakumar B, et al. Among authors: zeldenrust s. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):53-56. doi: 10.1016/j.clml.2019.09.624. Epub 2019 Oct 9. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31685378 Free PMC article.
183 results